Understanding proteins in small cell lung cancer
Circulating Metabolites and Tumor-derived Extravesicular Proteins in Small Cell Lung Cancer
Aalborg University Hospital · NCT05623956
This study looks at proteins in the blood of people newly diagnosed with small cell lung cancer to see how they change during standard chemotherapy treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Aalborg University Hospital (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Aalborg, Region North Jutland) |
| Trial ID | NCT05623956 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze tumor-derived circulating extracellular vesicle proteins in patients newly diagnosed with small cell lung cancer (SCLC). It will involve 50 patients who are set to receive standard chemotherapy with Carboplatin and Etoposide, alongside blood samples from 50 healthy donors for comparison. Blood samples will be collected before chemotherapy and after two cycles, with imaging performed before treatment and after three cycles to assess disease progression.
Who should consider this trial
Good fit: Ideal candidates are individuals with newly diagnosed small cell lung cancer who are eligible for standard chemotherapy.
Not a fit: Patients with active second malignancies or those who have received prior treatment for malignant diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of biomarkers in small cell lung cancer, potentially leading to improved treatment strategies.
How similar studies have performed: While this approach is focused on proteomics in SCLC, similar studies in other cancer types have shown promise in identifying biomarkers, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Written and signed informed consent * Histopathologically and/or cytologically newly-diagnosed SCLC * Measurable disease on CT scans * Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide Exclusion Criteria: * Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ * Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ * Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed) * Treatment with any other investigational agent
Where this trial is running
Aalborg, Region North Jutland
- Aalborg University Hospital — Aalborg, Region North Jutland, Denmark (RECRUITING)
Study contacts
- Principal investigator: Weronika Szejniuk, MD, PhD — Aalborg University Hospital
- Study coordinator: Borgen Dalsgaard
- Email: anbd@rn.dk
- Phone: 97606989
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Small Cell Lung Cancer, Proteomics, Biomarkers